CoChat

Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer

Open access

The DOI matches its Crossref record; 49 of the 51 references it cites were found in a registry or an index; 37 of the 46 sources its claims cite were checked for support.

Abstract

Current KRAS G12C (OFF) inhibitors that target inactive GDP-bound KRAS G12C cause responses in less than half of patients and these responses are not durable. A class of RAS G12C (ON) inhibitors that targets active GTP-bound KRAS G12C blocks ERK signaling more potently than the inactive-state inhibitors. Sensitivity to either class of agents is strongly correlated with inhibition of mTORC1 activity. We have previously shown that PI3K/mTOR and ERK-signaling pathways converge on key cellular processes and that inhibition of both pathways is required for inhibition of these processes and for significant antitumor activity. We find here that the combination of a KRAS G12C inhibitor with a selective mTORC1 kinase inhibitor causes synergistic inhibition of Cyclin D1 expression and cap-dependent translation. Moreover, BIM upregulation by KRAS G12C inhibition and inhibition of MCL-1 expression by the mTORC1 inhibitor are both required to induce significant cell death. In vivo, this combination causes deep, durable tumor regressions and is well tolerated. This study suggests that the ERK and PI3K/mTOR pathways each mitigate the effects of inhibition of the other and that combinatorial inhibition is a potential strategy for treating KRAS G12C -dependent lung cancer.

Overview

CoChat Summary

TL;DR

Combining active-state KRASG12C inhibitors with selective mTORC1 kinase inhibitors synergistically blocks Cyclin D1 expression, cap-dependent translation, and anti-apoptotic MCL-1 while inducing BIM, causing cell death and durable tumor regressions in KRASG12C NSCLC models. The study supports clinical evaluation of KRASG12C plus mTORC1 inhibition in KRASG12C-mutant lung cancer.

Key findings

  • Active-state KRASG12C inhibitors RM-018 and RMC-4998 inhibited ERK output more potently and durably than inactive-state inhibitors; H358, LU65, and H2122 were most sensitive to RM-018 with IC50 values more than 10-fold lower than adagrasib, and RMC-4998 had IC50 values approximately 10-fold lower than RM-018. In H23, adagrasib-treated cells showed rebound in 8/9 ERK-regulated mRNAs at 24 h versus 3/9 with RM-018; in LU65, 7 mRNAs remained below 10% of baseline at 24 h with RM-018 versus 2 with adagrasib.
  • Sensitivity to KRASG12C inhibition correlated with PI3K/mTOR pathway inhibition: inhibition of cell growth by sotorasib and AZD8037 correlated with pAKT S473, p-p70S6K T389, and p4E-BP1 S65 with R² values of 0.53–0.77, whereas pERK inhibition was not significantly correlated (R² = 0.11).
  • RM-018 plus the mTORC1-selective bi-steric inhibitor RMC-6272 caused greater than 80% average growth reduction across KRASG12C NSCLC cell lines and significantly reduced viability versus either agent alone in every model tested. In vivo, RMC-4998 plus RMC-6272 caused almost complete regression in H2122 xenografts over 50 days, minimal residual tumors by day 70 in H2030, and dramatic durable shrinkage in 3 of 4 PDX models, with no significant body weight loss or hyperglycemia.
  • Mechanistically, the combination increased G0/G1 cells by 110% versus ~50% for each single agent, induced 3–4-fold more cell death than controls, blocked Cyclin D1 at transcriptional and translational levels, and required BIM induction plus MCL-1 reduction for apoptosis.

Methods

  • Preclinical study using a panel of KRASG12C-mutant NSCLC cell lines and KRASG12S/EGFR-mutant controls; assays included CellTiter-Glo viability, immunoblotting, qPCR, RAS-GTP pulldown, m7GTP cap-binding, siRNA knockdown, MCL-1 overexpression, EdU-DAPI flow cytometry, annexin V/PI, and caspase 3/7 activity.
  • In vivo studies used H2122 and H2030 cell-line-derived xenografts and four KRASG12C-mutant lung PDX models in athymic or NSG mice; treatments included RMC-4998 80 mg/kg daily oral gavage, RMC-6272 6 mg/kg weekly intraperitoneal, RMC-6291 100 mg/kg daily oral gavage, and RMC-5552 10 mg/kg weekly intraperitoneal, with tumor volumes measured by calipers.
  • Statistical analysis used two-sided t tests or one-way ANOVA with post-hoc tests; viability data were n = 8 replicates, qPCR/flow data n = 3, and xenograft/PDX cohorts generally n = 5–8 mice per group.

Limitations

  • The paper states that the mechanistic basis for differential PI3K/mTOR sensitivity is not clear, that further questions remain about molecular determinants of RAS dependency of PI3K/mTOR signaling, and that the role of coexistent genetic mutations and complexity of survival/translation regulation need more investigation. It also notes that LX699, which harbored an uncharacterized MEK2 G214W mutation, did not regress with the combination and may represent a resistance mechanism.
  • Evident from the text: all findings are preclinical, using cell lines, xenografts, and PDX models, with no human clinical efficacy or safety data; several in vivo cohorts are small (n = 5–8 mice), and the study relies on tool compounds and investigational agents rather than approved therapies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-024-50063-z

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Active-state KRASG12C inhibitors inhibit ERK pathway output more potently and durably than inactive-state KRASG12C inhibitors. Cell viability data of KRASG12C mutant cell lines following treatment with (a) inactive-state KRASG12C inhibitors or (b) active-state KRASG12C inhibitors for 72 h. Data are the mean ± SD of n = 8 experimental replicates. c LU65 and H23 cell lines were treated with 100 nM Adagrasib or 100 nM RM-018 for the indicated times and lysates were analyzed by immunoblot. In parallel, the amount of active GTP-bound KRAS was determined by a RAS-GTP pulldown assay. d The mRNA expression of the indicated target genes was determined by quantitative PCR in LU65 and H23 cell lines following 100 nM Adagrasib or 100 nM RM-018 treatment for the indicated times. The data shown represent the means ± SD of n = 3 experimental replicates. P values are shown and were calculated by two-sided t test.
Fig. 1 Active-state KRASG12C inhibitors inhibit ERK pathway output more potently and durably than inactive-state KRASG12C inhibitors. Cell viability data of KRASG12C mutant cell lines following treatment with (a) inactive-state KRASG12C inhibitors or (b) active-state KRASG12C inhibitors for 72 h. Data are the mean ± SD of n = 8 experimental replicates. c LU65 and H23 cell lines were treated with 100 nM Adagrasib or 100 nM RM-018 for the indicated times and lysates were analyzed by immunoblot. In parallel, the amount of active GTP-bound KRAS was determined by a RAS-GTP pulldown assay. d The mRNA expression of the indicated target genes was determined by quantitative PCR in LU65 and H23 cell lines following 100 nM Adagrasib or 100 nM RM-018 treatment for the indicated times. The data shown represent the means ± SD of n = 3 experimental replicates. P values are shown and were calculated by two-sided t test.CC BY · PubMed Central
Fig. 2 Sensitivity of NSCLC cell lines to KRASG12C inhibitors is highly correlated with their inhibition of PI3K-AKT-mTOR signaling. a Immunoblots of KRASG12C mutant cell lines treated with 1 µM AZD8037 for the indicated times. Scattered plot of cell viability for the KRASG12C mutant cell lines following 72 h treatment plotted against quantified immunoblot intensities of the indicated phosphorylated protein normalized against the respective total protein after 24 h treatment. The plots show 12 cell lines plotted twice each for independent experiments with either 1 µM Sotorasib or 1 µM AZD8037. R2 calculated by linear regression. c Same as (b) but with 12 cell lines plotted once each after treatment with 100 nM RM-018. d Cell viability as percentage change from control of KRASG12C mutant cell lines treated for 72 h with BYL719 1 µM, MK2206 1 µM, Rapamycin 10 nM, RMC-6272 1 nM, RapaLink-1 10 nM, Adagrasib 100 nM, RM-018 100 nM, or combination treatments as indicated. Each point represents the mean of n = 8 experimental replicates, and the boxes represent the mean of the cell lines. e Cell viability as percentage change from control for KRASG12C mutant cell lines treated with either 100 nM RM-018, 1 nM RMC-6272 or the combination for 72 h. Data are means ± SD for n = 8 experimental replicates. P values are shown and were calculated by one-way ANOVA with post-hoc Tukey’s test. The status of genetic co-alterations is shown.
Fig. 2 Sensitivity of NSCLC cell lines to KRASG12C inhibitors is highly correlated with their inhibition of PI3K-AKT-mTOR signaling. a Immunoblots of KRASG12C mutant cell lines treated with 1 µM AZD8037 for the indicated times. Scattered plot of cell viability for the KRASG12C mutant cell lines following 72 h treatment plotted against quantified immunoblot intensities of the indicated phosphorylated protein normalized against the respective total protein after 24 h treatment. The plots show 12 cell lines plotted twice each for independent experiments with either 1 µM Sotorasib or 1 µM AZD8037. R2 calculated by linear regression. c Same as (b) but with 12 cell lines plotted once each after treatment with 100 nM RM-018. d Cell viability as percentage change from control of KRASG12C mutant cell lines treated for 72 h with BYL719 1 µM, MK2206 1 µM, Rapamycin 10 nM, RMC-6272 1 nM, RapaLink-1 10 nM, Adagrasib 100 nM, RM-018 100 nM, or combination treatments as indicated. Each point represents the mean of n = 8 experimental replicates, and the boxes represent the mean of the cell lines. e Cell viability as percentage change from control for KRASG12C mutant cell lines treated with either 100 nM RM-018, 1 nM RMC-6272 or the combination for 72 h. Data are means ± SD for n = 8 experimental replicates. P values are shown and were calculated by one-way ANOVA with post-hoc Tukey’s test. The status of genetic co-alterations is shown.CC BY · PubMed Central
Fig. 3 The combination of KRASG12C and mTORC1 selective inhibition causes durable tumor regressions in KRASG12C mutant NSCLC models in vivo. a H2122 xenografts were treated with vehicle, RMC-6272 6 mg/kg weekly, RMC-4998 80 mg/kg daily, or the combination. Tumor volumes were plotted from the start of treatment (mean ± SEM, n = 5 mice in each cohort). P values are shown and were calculated by two-sided t-test. b H2122 xenografts were treated 10 days post-implant with the vehicle, RMC-6291 100 mg/kg daily, RMC-5552 10 mg/kg weekly, or the combination. Tumor volumes were plotted over time from the start of treatment (mean ± SEM, n = 8 mice in each cohort). P values are shown and were calculated by two-sided t-test. c Four different KRASG12C mutant lung PDX tumors were implanted into NSG mice. PDXs were treated with the vehicle, RMC-6272 6 mg/kg weekly, RMC-4998 80 mg/kg daily, or the combination. Tumor volumes were plotted over time from the start of treatment (mean ± SEM, n = 5 mice in each cohort for LX349 and LX699, n = 6 mice in each cohort for LX369 and LX337). P values are shown and were calculated by two-sided t test. d Waterfall plot showing the percentage change in tumor volume (relative to initial volume) for individual LX349 (left) and LX369 (right) tumors at the end of treatment. P values are shown and were calculated by one-way ANOVA with post-hoc Tukey’s test.
Fig. 3 The combination of KRASG12C and mTORC1 selective inhibition causes durable tumor regressions in KRASG12C mutant NSCLC models in vivo. a H2122 xenografts were treated with vehicle, RMC-6272 6 mg/kg weekly, RMC-4998 80 mg/kg daily, or the combination. Tumor volumes were plotted from the start of treatment (mean ± SEM, n = 5 mice in each cohort). P values are shown and were calculated by two-sided t-test. b H2122 xenografts were treated 10 days post-implant with the vehicle, RMC-6291 100 mg/kg daily, RMC-5552 10 mg/kg weekly, or the combination. Tumor volumes were plotted over time from the start of treatment (mean ± SEM, n = 8 mice in each cohort). P values are shown and were calculated by two-sided t-test. c Four different KRASG12C mutant lung PDX tumors were implanted into NSG mice. PDXs were treated with the vehicle, RMC-6272 6 mg/kg weekly, RMC-4998 80 mg/kg daily, or the combination. Tumor volumes were plotted over time from the start of treatment (mean ± SEM, n = 5 mice in each cohort for LX349 and LX699, n = 6 mice in each cohort for LX369 and LX337). P values are shown and were calculated by two-sided t test. d Waterfall plot showing the percentage change in tumor volume (relative to initial volume) for individual LX349 (left) and LX369 (right) tumors at the end of treatment. P values are shown and were calculated by one-way ANOVA with post-hoc Tukey’s test.CC BY · PubMed Central
Fig. 4 Combined inhibition of KRASG12C and mTORC1 blocks Cyclin D1 expression at the transcriptional and translational levels. a H1373 cells were treated with 1 nM RMC-6272, 100 nM RM-018, or the combination for 24 h. Cell cycle states were detected with EdU-DAPI-based flow cytometry. b H1373 and H2122 cells were treated with either 100 nM RM-018, 1 nM RMC-6272, or the combination for the indicated times, and lysates were analyzed by immunoblot. c Schema of the flow for the methionine starvation experiment in (d). d H1373 cells were cultured in methionine starved medium for 24 h, followed by adding back complete media (CM) alone, or with either 1 nM RMC-6272 or 50 µg/ml cycloheximide (CHX) for the indicated times, and lysates were analyzed by immunoblot. e Cyclin D1 mRNA levels were determined by quantitative PCR in H1373, HOP62, H2030, and H2122 cells following 1 nM RMC-6272, 100 nM RM-018, or the combination for 24 h. The data shown represent the means ± SD of n = 3 experimental replicates. P values are shown and were calculated by one-way ANOVA with post-hoc Tukey’s test.
Fig. 4 Combined inhibition of KRASG12C and mTORC1 blocks Cyclin D1 expression at the transcriptional and translational levels. a H1373 cells were treated with 1 nM RMC-6272, 100 nM RM-018, or the combination for 24 h. Cell cycle states were detected with EdU-DAPI-based flow cytometry. b H1373 and H2122 cells were treated with either 100 nM RM-018, 1 nM RMC-6272, or the combination for the indicated times, and lysates were analyzed by immunoblot. c Schema of the flow for the methionine starvation experiment in (d). d H1373 cells were cultured in methionine starved medium for 24 h, followed by adding back complete media (CM) alone, or with either 1 nM RMC-6272 or 50 µg/ml cycloheximide (CHX) for the indicated times, and lysates were analyzed by immunoblot. e Cyclin D1 mRNA levels were determined by quantitative PCR in H1373, HOP62, H2030, and H2122 cells following 1 nM RMC-6272, 100 nM RM-018, or the combination for 24 h. The data shown represent the means ± SD of n = 3 experimental replicates. P values are shown and were calculated by one-way ANOVA with post-hoc Tukey’s test.CC BY · PubMed Central
Fig. 5 Combined inhibition of KRASG12C and mTORC1 kinase synergize to induce apoptosis by inducing BIM and reducing MCL-1 expression. a H1373 cells were treated with 100 nM RM-018, 1 nM RMC-6272, or the combination for 72 h, and analyzed by FACS to quantify annexin V positive cells. Data are means ± SD for n = 3 experimental replicates. P values are shown and were calculated by one-way ANOVA with post-hoc Tukey’s test. b Immunoblot analysis of lysates from H1373 and H2122 cells treated with 100 nM RM-018, 1 nM RMC-6272, or the combination for the indicated times. c H1373 cells were cultured in methionine-starved medium for 24 h, then replaced with complete media (CM) alone, or with either 1 nM RMC-6272 or 50 µg/ml cycloheximide (CHX) for the indicated times, and lysates were analyzed by immunoblot. d H1373 cells were transfected with siRNAs targeting BIM, PUMA or scramble (scr) siRNA and incubated for 24 h. The cells were then treated with the combination of 1 nM RMC-6272 and 100 nM RM-018 for 48 h and lysates were analyzed by immunoblot. e H1373 cells infected with a GFP control or MCL-1 expressing lentiviral plasmid were treated with 100 nM RM-018, 1 nM RMC-6272, or the combination for 48 h and lysates were analyzed by immunoblot. f H2122-derived xenografts were treated with vehicle, RMC-6272 6 mg/kg once, RMC-4998 80 mg/kg x 2 doses 24 h apart, or the combination. 48 h after start of treatment, the tumors were collected, lysed and immunoblotted with the indicated antibodies. M1, M2, M3 represent individual mice from each treatment condition. g IHC analysis of H2122-derived xenograft tumors collected 8 h after treatment with vehicle, RMC-5552 (10 mg/kg, ip), RMC-6291 (100 mg/kg, po), or the combination. The magnification of all IHC slides are 40x, scale bars are 100 µm. h Quantification of Cleaved Caspase 3 IHC analysis shown in (g). The data shown represent the means ± SD of n = 3 experimental replicates.
Fig. 5 Combined inhibition of KRASG12C and mTORC1 kinase synergize to induce apoptosis by inducing BIM and reducing MCL-1 expression. a H1373 cells were treated with 100 nM RM-018, 1 nM RMC-6272, or the combination for 72 h, and analyzed by FACS to quantify annexin V positive cells. Data are means ± SD for n = 3 experimental replicates. P values are shown and were calculated by one-way ANOVA with post-hoc Tukey’s test. b Immunoblot analysis of lysates from H1373 and H2122 cells treated with 100 nM RM-018, 1 nM RMC-6272, or the combination for the indicated times. c H1373 cells were cultured in methionine-starved medium for 24 h, then replaced with complete media (CM) alone, or with either 1 nM RMC-6272 or 50 µg/ml cycloheximide (CHX) for the indicated times, and lysates were analyzed by immunoblot. d H1373 cells were transfected with siRNAs targeting BIM, PUMA or scramble (scr) siRNA and incubated for 24 h. The cells were then treated with the combination of 1 nM RMC-6272 and 100 nM RM-018 for 48 h and lysates were analyzed by immunoblot. e H1373 cells infected with a GFP control or MCL-1 expressing lentiviral plasmid were treated with 100 nM RM-018, 1 nM RMC-6272, or the combination for 48 h and lysates were analyzed by immunoblot. f H2122-derived xenografts were treated with vehicle, RMC-6272 6 mg/kg once, RMC-4998 80 mg/kg x 2 doses 24 h apart, or the combination. 48 h after start of treatment, the tumors were collected, lysed and immunoblotted with the indicated antibodies. M1, M2, M3 represent individual mice from each treatment condition. g IHC analysis of H2122-derived xenograft tumors collected 8 h after treatment with vehicle, RMC-5552 (10 mg/kg, ip), RMC-6291 (100 mg/kg, po), or the combination. The magnification of all IHC slides are 40x, scale bars are 100 µm. h Quantification of Cleaved Caspase 3 IHC analysis shown in (g). The data shown represent the means ± SD of n = 3 experimental replicates.CC BY · PubMed Central
Fig. 6 KRASG12C inhibition and mTORC1 inhibition cause synergistic reduction in cap-dependent translation. a H1373 and H2122 cells were transfected with two different siRNAs targeting eIF4E or scramble (scr) siRNA and cultured for 24 h. Media was replaced with or without 100 nM RM-018 and cells were treated for an additional 48 h and analyzed by FACS to quantify annexin positive cells. Data are means ± SD for n = 3 experimental replicates. P values are shown and were calculated by one-way ANOVA and post-hoc Tukey’s test. b H1373 and H2122 cells were transfected with two different siRNAs targeting eIF4E or scramble (scr) siRNA and cultured for 24 h. Media was replaced with or without 100 nM RM-018 and cells were treated for an additional 48 h, and lysates were analyzed by immunoblot. c H1373 and H2122 cells were treated with 1 nM RMC-6272, 100 nM RM-018, or the combination for the indicated times, followed by incubation with m7GTP-conjugated beads, and lysates were probed by immunoblot in parallel with whole cell extracts (input). d H2122 cells were treated with 100 µM Z-VAD-FMK, 1 nM RMC-6272, 100 nM RM-018, or indicated combinations for 48 h, and lysates were analyzed by immunoblot.
Fig. 6 KRASG12C inhibition and mTORC1 inhibition cause synergistic reduction in cap-dependent translation. a H1373 and H2122 cells were transfected with two different siRNAs targeting eIF4E or scramble (scr) siRNA and cultured for 24 h. Media was replaced with or without 100 nM RM-018 and cells were treated for an additional 48 h and analyzed by FACS to quantify annexin positive cells. Data are means ± SD for n = 3 experimental replicates. P values are shown and were calculated by one-way ANOVA and post-hoc Tukey’s test. b H1373 and H2122 cells were transfected with two different siRNAs targeting eIF4E or scramble (scr) siRNA and cultured for 24 h. Media was replaced with or without 100 nM RM-018 and cells were treated for an additional 48 h, and lysates were analyzed by immunoblot. c H1373 and H2122 cells were treated with 1 nM RMC-6272, 100 nM RM-018, or the combination for the indicated times, followed by incubation with m7GTP-conjugated beads, and lysates were probed by immunoblot in parallel with whole cell extracts (input). d H2122 cells were treated with 100 µM Z-VAD-FMK, 1 nM RMC-6272, 100 nM RM-018, or indicated combinations for 48 h, and lysates were analyzed by immunoblot.CC BY · PubMed Central

Verification

Claims the paper makes

19 Valid · 1 Not valid · 5 Not checked · 136 Own results and interpretations

71 more claims · 4 with their cited sources checked

Create a free account to see all 161 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 18
  • It may state two separate claims as one. 73
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 49 references

Cited by

See all 41

Metadata

Authors
Kitai, H., Choi, P. H., Yang, Y. C., Boyer, J. A., Whaley, A., Pancholi, P., Thant, C., Reiter, J., Chen, K., Markov, V., Taniguchi, H., Yamaguchi, R., Ebi, H., Evans, J., Jiang, J., Lee, B., Wildes, D., de Stanchina, E., Smith, J. A. M., Singh, M., & Rosen, N.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Revolution Medicines (United States) (US)
  • Aichi Cancer Center (JP)
Corresponding author
  • Singh, Mallika
  • Rosen, Neal
Venue
Nature Communications
Published
2024-07-19
Volume
15
Issue
1
Pages
6076-6076
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4400839787
Cited by
41
References
51
Citations by year
2026: 19 · 2025: 16 · 2024: 6
FWCI
5.56
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA210085)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
KRAS G12C inhibitors, mTORC1 inhibition, non-small cell lung cancer, combination therapy, ERK signaling, PI3K/mTOR pathway, cyclin D1, cap-dependent translation, building information modeling, Mcl-1, apoptosis, tumor regression
MeSH terms
Bcl-2-Like Protein 11, Mechanistic Target of Rapamycin Complex 1, Animals, Carcinoma, Non-Small-Cell Lung, Drug Synergism, Female, Humans, Lung Neoplasms, Signal Transduction, Proto-Oncogene Proteins p21(ras), Cyclin D1, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, TOR Serine-Threonine Kinases, Myeloid Cell Leukemia Sequence 1 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer. https://app.cochat.ai/papers/10.1038/s41467-024-50063-z
The paper
Kitai, H., Choi, P. H., Yang, Y. C., Boyer, J. A., Whaley, A., Pancholi, P., Thant, C., Reiter, J., Chen, K., Markov, V., Taniguchi, H., Yamaguchi, R., Ebi, H., Evans, J., Jiang, J., Lee, B., Wildes, D., de Stanchina, E., Smith, J. A. M., . . . Rosen, N. (2024). Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer. Nature Communications. https://doi.org/10.1038/s41467-024-50063-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.